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Abstract
Background: Premature shortening of leukocyte telomere length has been proposed as a novel mechanism by which
depression may confer increased risk of adverse cardiovascular events. Prior studies demonstrating associations of
depression and depressive symptoms with shorter leukocyte telomere length were small, included selected psychiatric
outpatients, were based on convenience samples, and/or adjusted for a limited number of possible confounding factors.
Methods and Findings: We examined the associations of depressive symptoms, probable depressive disorder, and specific
depressive symptom clusters, as assessed by the Center for Epidemiological Studies—Depression (CES-D) scale, with
leukocyte telomere length, measured by using a real-time PCR method, in 2,225 apparently healthy participants from the
1995 Nova Scotia Health Survey population-based study. The mean age was 48.2618.9 years; 49.9% of participants were
female; and the mean CES-D score was 7.467.9. The mean telomere length was 5,3016587 base pairs. In an unadjusted
model, depressive symptoms were significantly associated with longer leukocyte telomere length (B = 27.6 base pairs per
standard deviation increase in CES-D, 95% confidence interval [CI] = 3.1–52.1, p= 0.027). This association was no longer
significant after adjustment for age and sex (B = 9.5, 95% CI =214.6–33.6, p= 0.44) or after further adjustment for body mass
index, Framingham risk score and previous history of ischemic heart disease (all p’s$0.37). Neither probable depressive
disorder nor specific depressive symptom clusters were independently associated with leukocyte telomere length.
Conclusions: Concurrent depressive symptoms were not associated with leukocyte telomere length in a large,
representative, population-based study.
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Introduction
Depressive symptoms and depressive disorders are important
causes of disability worldwide. [1] Depression has also been found
to predict incident and recurrent cardiovascular disease (CVD)
events and mortality [2,3]; however, the pathophysiology and
mechanisms underlying the association between depression and
CVD events remains poorly understood. Accelerated cellular
aging has been proposed as a novel pathogenic process associated
with depression [4] and a biological mechanism by which
depressive symptoms may confer increased risk of adverse
cardiovascular events due to the role of vascular cellular aging in
atherosclerosis development [5]. Telomeres are repetitive, non-
coding DNA sequences located at the end of chromosomes that
promote genome stability by protecting against aberrant DNA
repair mechanisms. Telomere length has been proposed as a
biomarker for biological aging [6], and shorter leukocyte telomere
length has been associated with a variety of age-related disorders,
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including atherosclerosis [7], cardiovascular diseases [8,9], de-
mentia [10], and cancer [11].
Perceived stress and chronicity of stress have both been linked to
shorter leukocyte telomere length in premenopausal women [12].
Following an early study by Simon and colleagues that reported
significantly shorter leukocyte telomere length in a clinical sample
of 44 patients with chronic mood disorders compared to 44 age-
matched controls without psychiatric disorders [4], some studies
have found an association of depressive symptoms and major
depressive disorder (MDD) with shorter leukocyte telomere lengths
[13,14], while others have not [15,16]. The enrollment of selected
participants such as psychiatric patients, small sample sizes, and
adjustment for a limited number of possible confounding factors
including cardiovascular risk factors may have contributed to these
divergent results.
We examined the association between depression and leukocyte
telomere length in 2,225 participants from the population-based
1995 Nova Scotia Health Survey study, and determined whether
this association was independent of age, sex, body mass index and
other cardiovascular risk factors. Given that depression is a
complex phenotype [17] and that specific depressive symptom
clusters may be differentially related to cardiovascular prognosis
[18] and biological factors related to cardiovascular prognosis
[19,20], we secondarily investigated whether specific depressive




The 1995 Nova Scotia Health Survey (NSHS95) is a
representative, population-based survey implemented by Heart
Health Nova Scotia and the Nova Scotia Department of Health.
Potential participants were randomly identified based on a
probability sample by Statistics Canada, the national statistical
agency and census bureau, and were selected to be representative
of the Nova Scotian population by age, sex, and geographic
location. Participants consisted of non-institutionalized, non-
pregnant Nova Scotians, ages 18 years or older, and listed in the
registry of Medical Services Insurance, the government-sponsored
universal health insurance plan. Of 4,500 targeted participants,
3,227 (72%) provided informed consent and were enrolled. As
previously reported [21], propensity score analyses revealed no
meaningful response biases between those enrolling versus those
not enrolling in the study. The current study and analyses were
approved by the institutional review boards of Dalhousie
University, Halifax, Nova Scotia, and Columbia University
Medical Center, New York, NY, and conform to the ethical
guidelines of the Declaration of Helsinki. Participants provided
written informed consent to participate in this study, which
allowed for linkage to their health care use data and for the storage
and future use of blood assays.
For this analysis, we excluded 1,002 participants who had
depressive symptom scores but did not have assessments of
leukocyte telomere length (n=938), had assessments of leukocyte
telomere length but were missing assessments of depressive
symptoms (n=17), or had no assessment of either measure
(n=47). Therefore, a final cohort of 2,225 participants was
available for the present analysis. Compared to the 1,002
participants who did not have assessments of leukocyte telomere
length or depressive symptoms, the 2,225 participants in this
analysis were significantly less likely to be active smokers but did
not differ significantly in age, sex, body mass index (BMI), systolic
and diastolic blood pressure, or Framingham risk score (as defined
below). Compared to the 938 participants who had depressive
symptom scores but did not have assessments of leukocyte
telomere length, the 2,225 participants included in the present
analyses had significantly but modestly lower depressive symptom
scores (mean6SD, 7.467.9 versus 8.368.5, respectively,
p=0.004).
Nova Scotia Health Survey procedures
From March through November 1995, a group of trained
public health nurses contacted potentially eligible individuals and
interviewed those who agreed to participate. Those who were
interviewed also visited a health care clinic approximately one
week afterwards. During the clinic visit, height and weight were
measured, a comprehensive set of cardiovascular risk factors was
assessed, and a full medical history was conducted. Blood was
drawn at the clinic visit and processed for plasma and
buffy coat samples. Medication use was recorded at a home
visit.
Measurement of leukocyte telomere length
DNA was extracted from frozen buffy coat samples. Leukocyte
telomere length measurements were performed on coded samples
by laboratory personnel blinded to participant characteristics.
Average leukocyte telomere length was determined using a
polymerase chain reaction (PCR) method modified from that of
Cawthon and colleagues [9] by Kang and Honig (manuscripts in
preparation). Real-time PCR was performed using a CFX384
thermocycler (Biorad, Richmond, CA). The assay method was
optimized for use of both telomere (T) and single copy gene (S)
amplifications on the same 384-well plate, with reference standard
DNA samples on each plate. Test DNA samples each underwent
two triplicate PCR reactions, with use of ‘‘calibrator samples’’ for
correction of inter-plate variability. Amplification primers for
telomeres included Tfor: 59- CGGTTTGTTTGGGTT
TGGGTTTGGGT TTGGGTTTGGGTT-39 and Trev: 59-
GGCTTGCCTTACCCTTACCCTTAC CCTTACCCTTAC
CCT-39, and for single copy gene (beta-globin) Sfor 59-
GCTTCTGACACA ACTGTGTTCACTA GC-39 and Srev 59-
CACCAACTTCATCCAC GTTCACC-39. Thermocycling pa-
rameters were 95uC610 min activation, followed by 34 cycles of
95uC615 sec, and 55uC6120 sec. Assay coefficient of variance
was 5% to 8%. Given that the T/S ratio depends on the particular
DNA standards used, T/S ratios were converted to telomere base
pairs using a formula (base pairs = (1,585 * T/S ratio)+3,582)
derived from co-analysis of selected DNA samples with both PCR
and terminal restriction fragment methods (non-radioactive
TeloTAGGG Telomere Length, Roche Diagnostics, Mannheim,
Germany). To allow comparisons between our study and others,
we present telomere length results in base pairs. Given that the
telomere base pairs are derived via a linear transform of the T/S
ratio, all statistical analyses yield the same results regardless of
whether base pairs or T/S ratio is used.
Measurement of depressive symptoms
Depressive symptoms were measured using the Center for
Epidemiological Studies—Depression (CES-D) scale [22], a 20-
item self-report instrument designed for use in epidemiologic
studies as a measure of current depressive symptoms. Analyses
were performed using the scale as a continuous measure
(Cronbach’s alpha= 0.88 in this sample) and as a dichotomous
measure, with cutpoints of CES-D$10 or CES-D$16 as markers
of ‘‘elevated depressive symptoms’’ and ‘‘probable depressive
disorder,’’ respectively. The CES-D$16 cutpoint has been shown
to have acceptable specificity and sensitivity in relation to
Depression and Telomere Length
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interview-based diagnoses of MDD [23,24]. We have also
previously shown that elevated depressive symptoms, defined as
CES-D$10, are associated with an increased risk of ischemic
heart disease events [25].
Baseline demographic and risk factors
Demographic, anthropometric, and other cardiovascular risk
factors that have been linked to leukocyte telomere length—age
[26], sex [10,27], elevated blood pressure [28], diabetes [29],
increased BMI [30,31], smoking status [31], and prevalent
ischemic heart disease [32]—were assessed at baseline. Partici-
pants’ ages and sex were recorded from the provincial health
insurance registry and verified by the interviewer. Weight and
height were measured twice, averaged, and used to calculate BMI
(as weight in kilograms divided by height in meters squared).
Registered nurses used manual sphygmomanometers with appro-
priately sized blood pressure cuffs to measure systolic blood
pressure (SBP) and diastolic blood pressure (DBP); two readings at
home and two at the clinic visit were averaged to determine resting
values of each. Total cholesterol, high-density lipoprotein (HDL)
cholesterol, and triglyceride levels were assayed from plasma
samples by the Lipid Research Laboratory, University of Toronto,
Ontario [33]. Low-density lipoprotein (LDL) cholesterol was
calculated using the Friedewald formula [34]. History of diabetes
was ascertained by self-report. Those who reported smoking
currently or in the past year were considered smokers; all others
were considered nonsmokers. In order for an efficient use of CVD
risk factors in adjusted models, Framingham risk score was
calculated using age, sex, total and HDL cholesterol levels, blood
pressure, and history of diabetes and cigarette smoking [35]. Lipid-
lowering medication use was defined as the use of statins, fibrates,
bile acid sequestrants, or nicotinic acid. Prior ischemic heart
disease was defined from a search of hospitalization data five years
prior to the baseline interview and based on International
Classification of Disease (ICD-9) codes 410.x through 414.x.
Additional details of study procedures have been published
previously [36].
Statistical analyses
We used SPSS version 18 (IBM, Armonk, NY, USA) to analyze
the association of depressive symptoms and probable depressive
disorder with leukocyte telomere length. To determine the
unadjusted association between depressive symptoms and leuko-
cyte telomere length, we conducted linear regression analyses with
leukocyte telomere length as the dependent variable and
depressive symptoms as the independent variable (first treated
continuously and then as one of two dichotomous variables to
indicate either elevated depressive symptoms (CES-D$10) or
probable depressive disorder (CES-D$16). We then adjusted this
model for potential clinical-demographic confounders of the
putative telomere-depression association. Model 1 adjusted for
age and sex; model 2 additionally adjusted for Framingham risk
score; model 3 additionally adjusted for BMI; and model 4
additionally adjusted for previous ischemic heart disease. Effect
size modification was assessed by checking for interactions
between depressive symptoms and participant characteristics
including age ($75 years vs. ,75 years), sex, BMI (,25 kg/m2,
25–29.9 kg/m2, $30 kg/m2), and Framingham risk score (.10%
vs. #10%) using likelihood-ratio tests after interaction terms were
added to the full model. Sensitivity analyses were conducted
excluding those with prior ischemic heart disease.
Secondary analyses were conducted to test whether specific
depressive symptom clusters were associated with leukocyte
telomere length. To do so, we computed four subscales of the
CES-D based upon previously reported factor analytic studies
showing that this measure has a four-factor structure [37]. These
four subscales were: depressed affect (items 3, 6, 9, 10, 14, 17, and
18), somatic concerns (items 1, 2, 5, 7, 11, 13, and 20), positive
affect (items 4, 8, 12, and 16), and interpersonal problems (items
15 and 19). The set of five unadjusted and adjusted linear
regression models discussed above were used to examine the
association of leukocyte telomere length with each depressive
symptom cluster, treated as a continuous measure. We additionally
investigated whether high versus low scores on each subscale
(defined as the fourth quartile versus the first quartile) was
associated with leukocyte telomere length in a similar series of
unadjusted and adjusted linear regression models.
Power analysis
Simon and colleagues [4] reported that those with a mood
disorder had significantly shorter leukocyte telomere lengths than
a non-psychiatric comparison group, controlling for age and sex.
From their regression analysis results, we calculated that the effect
size for their observed difference in adjusted group means was
d=20.67, which corresponds to a partial point-biserial correlation
of20.33. The effect size d for the association of leukocyte telomere
length and depression in other studies ranged from 20.83 to
20.59, corresponding to point-biserial correlations of 20.38 and
20.28, respectively. Although we hypothesize that the true
correlation is negative, there is clearly substantial uncertainty as
to the magnitude of the actual effect size. Nonetheless, with a
sample of 2,225 participants, the present study had greater than
99% power to detect a partial correlation#20.10, using a two-
tailed F-test of the corresponding regression coefficient for CES-D.
Correlations of magnitude less than 0.10 are unlikely to be of
theoretical or clinical interest.
Results
Clinical-demographic characteristics of the 2,225 NSHS95
participants who contributed data to the current analyses are
reported in Table 1. The mean age of the sample was 48.2618.9
years, and approximately 50% of the sample was female. The
mean leukocyte telomere length for the overall cohort was
5,3016587 base pairs, and the mean total score on the CES-D
was 7.467.9. Based on a cutpoint of $10 for the CES-D overall
score, 27.6% of participants had elevated depressive symptoms;
based on a cutpoint of $16 for the CES-D overall score, 12.1% of
participants had a probable depressive disorder.
Estimated mean leukocyte telomere lengths (in base pairs) by
depression status are shown in Figure 1. Depressive symptoms
(B= 27.6 base pairs per standard deviation increase in CES-D,
95% confidence interval [CI] = 3.1–52.1, p=0.027), elevated
depressive symptoms (CES-D$10: B= 59.6, 95% CI= 5.1–
114.2, p=0.032), and probable depressive disorder (CES-D$16:
B= 77.1, 95% CI= 2.3–151.9, p=0.043) were each associated
with longer leukocyte telomere length in unadjusted linear
regression models. However, after adjustment for age and sex,
these relations were no longer statistically significant (Table 2):
depressive symptoms (B= 9.5 base pairs per standard deviation
increase in CES-D, 95% CI=214.6–33.6, p=0.44), elevated
depressive symptoms (CES-D$10: B= 20.8, 95% CI=232.6–
74.3, p=0.45), and probable depressive disorder (CES-D$16:
B= 50.2, 95% CI=222.8–123.1, p=0.18) were not significantly
associated with leukocyte telomere length. Results were similar in
models that additionally adjusted for Framingham risk score, BMI,
and previous ischemic heart disease. Neither depressive symptoms
nor probable depressive disorder interacted with age, sex, or BMI
Depression and Telomere Length
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categories in the prediction of leukocyte telomere length in fully
adjusted models (all p’s$0.10). Results of analyses that excluded
participants with ischemic heart disease in the five years prior to
the baseline interview were similar to results of the primary
analyses. Specifically, depressive symptoms (B= 30.8 base pairs
per standard deviation increase in CES-D, 95% CI= 5.1–56.5,
p=0.019), elevated depressive symptoms (CES-D$10: B= 64.9,
95% CI= 8.1–121.7, p=0.025), and probable depressive disorder
(CES-D$16: B= 68.7, 95% CI=29.5–147.0, p=0.085) were
associated with leukocyte telomere length in unadjusted linear
regression models, but the association became non-significant in
the adjusted models (all p’s$0.26).
Secondary analyses of the association between depressive
symptom clusters and leukocyte telomere length were also all
non-significant. The continuous depressed affect, somatic con-
cerns, positive affect, and interpersonal difficulties subscales of the
CES-D each failed to significantly predict leukocyte telomere
length in either unadjusted or adjusted linear regression models (all
p’s$0.17). Further, high versus low scores on each of these
subscales (defined as the fourth quartile versus the first quartile)
were not associated with leukocyte telomere length (all p’s$0.10).
Discussion
In this sample of 2,225 apparently healthy participants from a
population-based study, we found that neither depressive symp-
toms nor probable depressive disorder were significantly associated
with leukocyte telomere length after adjustment for possible
confounding factors including age, sex, BMI and other cardiovas-
cular risk factors. These findings, based on one of the largest
cohorts to date in which the telomere-depression association has
been examined, fail to replicate those of several previous studies.
In addition, this study is among the first to examine the association
of leukocyte telomere length with specific depressive symptom
clusters, an important aim given the heterogeneity of the
depression phenotype [17] and the differential associations of
depressive symptom clusters with biological [19,20] and clinical
factors [18]. However, we did not observe an association between
leukocyte telomere length and any of the specific depressive
symptom clusters included in the current study.
It has been hypothesized that the increased risk of CVD
associated with depressive symptoms is in part
attributable to shortened telomeres—perhaps via increased
levels of oxidative stress or inflammation or decreased levels of
antioxidant enzymes [5]. Our findings show that depression is not
associated with shorter leukocyte telomere length in this popula-
tion-based sample. Although we did not consider cardiovascular
endpoints in the current analyses or directly test a mediational
model linking depression to cardiovascular outcomes via telomere
length, our failure to find an independent association between
depression and leukocyte telomere length suggests that telomere
length may not play an important role. Indeed, the single study
that directly tested whether premature leukocyte shortening
contributed to the excess morbidity and mortality associated with
depression in patients with stable coronary heart disease found
that adjusting for baseline leukocyte telomere length in depressed
patients did not affect the association between depression and
cardiovascular prognosis [5].
Several previous studies have found that psychosocial factors,
including depressive disorders and depressive symptoms, are
associated with shorter leukocyte telomere length. Simon and
colleagues [4], for instance, reported that leukocyte telomere
length was significantly shorter in a clinical sample of 44
individuals with chronic mood disorders—assessed by using a
structured clinical interview—compared to 44 non-psychiatric,
age-matched control participants. These findings were consistent
for the smaller subset of patients with MDD (n=15), and persisted
in analyses adjusted for chronological age, sex, and smoking
history. Lung and colleagues [14] likewise documented an
association between depression and shortened leukocyte telomere
length among 253 patients with psychiatrist-diagnosed MDD from
a hospital in Taiwan compared to a stratified, random household
sample of 411 community controls. Hartmann and colleagues also
reported significantly shorter telomere length in a non-randomly
selected group of 54 inpatients with diagnoses of MDD compared
to 20 healthy controls [13]. Differences between these previous
studies and the current one are that the previous studies were not
population-based and were relatively small compared to the
current study, thereby limiting the generalizability of their
reported results. These previous studies also considered a limited
set of confounding factors in adjusted analyses, and restricted their
definition of depression to MDD. Finally, other studies that have
examined the associations among leukocyte telomere length and
depression were limited to patients with prevalent cardiovascular
disease (e.g., patients with stable ischemic heart disease [5] or heart
failure [38]). The participants in our study were from a relatively
large and well-characterized population-based cohort, with a wide
range of depressive symptoms and CVD risk. Further, the sample
was of sufficient size to detect small but important associations
between depressive symptoms and telomere length, and our
analyses considered important covariates that may be associated
with shorter telomere length. Therefore, the lack of association
Table 1. Clinical-demographic characteristics of 2,225
participants in the 1995 Nova Scotia Health Survey (NSHS95)
study.
Clinical-demographic characteristic Value
Age, years 48.2 (18.9)
Female, n (%) 1,110 (49.9)
Smoking, n (%) 586 (26.3)
Body mass index, kg/m2 27.0 (5.5)
Diabetes mellitus, n (%) 101 (4.5)
Systolic blood pressure, mm Hg 126.0 (17.7)
Diastolic blood pressure, mm Hg 76.9 (9.6)
Low-density lipoproteins, nmol/l 3.3 (0.9)
High-density lipoproteins, nmol/l 1.3 (0.3)
Use of lipid-lowering medications, n (%) 42 (1.9)
Use of aspirin, n (%) 90 (4.0)
Framingham risk score points 2.1 (9.2)
Previous ischemic heart disease, n (%) 160 (7.2)
Telomere length, base pairs 5,301 (587)
CES-D total score (Range: 0–52) 7.4 (7.9)
Probable depressive disorder (CES-D$16), n (%) 269 (12.1)
Elevated depressive symptoms (CES-D$10), n (%) 613 (27.6)
CES-D depressed mood subscale score (Range: 0–20) 2.0 (3.2)
CES-D motor impairment subscale score (Range: 0–20) 3.6 (3.5)
CES-D lack of well-being subscale score (Range: 0–12) 1.5 (2.2)
CES-D interpersonal difficulties subscale score (Range: 0–6) 0.3 (0.8)
Values are means (standard deviation) except where noted otherwise.
Abbreviations. CES-D, Center for Epidemiologic Studies—Depression scale
doi:10.1371/journal.pone.0048318.t001
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between depressive symptoms and telomere length in our study
may be generalizable to a broader population.
Although significant findings have been reported, as described
above, not all studies have found an association between
depression and leukocyte telomere length. Wolkowitz and
colleagues failed to observe an association between leukocyte
telomere length in 18 untreated participants with MDD compared
to 17 apparently healthy controls [16]. In addition, Surtees and
Figure 1. Estimated mean leukocyte telomere length by depression status.
doi:10.1371/journal.pone.0048318.g001
Table 2. Associations between depressive symptoms, probable depressive disorder (CES-D$16), elevated depressive symptoms
(CES-D$10), and leukocyte telomere length.
Adjusted for Unstandardized regression coefficients predicting telomere length in base pairs, B (95% CI)
Depressive symptoms a P CES-D$16 P CES-D$10 P
– 27.6 (3.1–52.1) 0.027 77.1 (2.3–151.9) 0.043 59.6 (5.1–114.2) 0.032
Age and sex 9.5 (-14.6–33.6) 0.44 50.2 (-22.8–123.1) 0.18 20.8 (-32.6–74.3) 0.45
Age, sex, FRS 10.0 (-14.1–34.1) 0.42 51.4 (-21.6–124.3) 0.17 22.1 (-31.4–75.6) 0.42
Age, sex, FRS, BMI 9.3 (-15.1–33.7) 0.46 49.5 (-24.3–123.2) 0.19 22.5 (-31.5–76.6) 0.41
Age, sex, FRS, BMI, previous IHD 11.1 (-13.4–35.6) 0.37 52.8 (-20.9–126.6) 0.16 25.8 (-28.3–79.9) 0.35
Abbreviations: CES-D, Center for Epidemiologic Studies—Depression scale; FRS, Framingham risk score; BMI, body mass index; IHD, ischemic heart disease
aRegression coefficients represent the predicted number of base pairs by which leukocyte telomeres increase per standard deviation increase on the CES-D.
doi:10.1371/journal.pone.0048318.t002
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colleagues did not find evidence of an association between
leukocyte telomere length and lifetime MDD, past-year MDD,
or depressive symptoms among 4,441 women aged 41 to 80 years
from the population-based UK European Prospective Investiga-
tion into Cancer (EPIC)-Norfolk study [15]. However, they used a
self-assessment approach to assessing MDD that included restrict-
ed criteria from the Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV), and depressive symptoms were assessed with
the Short -Form 36 (SF-36), which is more often used as a measure
of quality of life than a measure of depression.
The absence of an association between concurrent depressive
symptoms and leukocyte telomere length may reflect the fact that
leukocyte telomere length is influenced by cumulative environ-
mental factors over time, whereas assessments of depressive
symptoms generally focus on only the past one-to-two weeks.
Indeed, although Wolkowitz and colleagues failed to find an
association of leukocyte telomere length with MDD or depressive
symptoms, telomere length was inversely correlated with lifetime
depression exposure, after controlling for age [16]. Specifically, the
average telomere length of outpatients who were both depressed
and had a high lifetime depression exposure (i.e., greater than the
median exposure) was significantly shorter than the average
telomere length of healthy controls who were individually matched
to cases by sex, ethnicity, and age. Studies of the association
between other psychosocial stressors and leukocyte telomere
length have likewise suggested the importance of considering
cumulative exposure to psychological stress. In a study by Epel and
colleagues, for instance, greater chronicity of caregiving stress (in
years), but not caregiving status itself, was associated with shorter
telomere length [12]. Our study did not include a measure of the
chronicity or lifetime duration of depressive symptoms. Similarly,
we did not have an assessment of early life trauma, which some
researchers have hypothesized as contributing to the association
between shorter telomere length and depression reported in
previous studies [13]. Indeed, some studies have linked shorter
leukocyte telomere length to childhood maltreatment or other
adverse childhood experiences among individuals without major
psychiatric disorders [39] and among those with posttraumatic
stress disorder [40]. However, not all studies have replicated this
association [41].
Our study is among the first to consider the association among
leukocyte telomere length and specific depressive symptom
clusters, and found that none of the specific depressive symptom
clusters were associated with telomere length. We have previously
shown that depression is a complex and occasionally chronic
cluster of diseases [18], and other authors have likewise discussed
limitations of the broad depression phenotype and proposals for
disaggregating its components [17]. Indeed, some studies suggest
that specific depressive symptom clusters (e.g., somatic symptoms)
are associated with cardiac prognosis while others (e.g., cognitive
symptoms) are not. Other research has found differential
associations between specific depressive symptom clusters and C-
reactive protein [19], heart rate variability, spontaneous baroreflex
sensitivity, and the cortisol awakening response [20]. Although no
single scale assesses all possible depressive symptoms or depressive
symptom clusters, our findings based on the CES-D do not
support differential associations between specific depressive
symptom clusters and telomere length, and thus do not support
telomere length as a mediator between depressive symptom
clusters and cardiac risk in this population.
The current study has several limitations. First, generalizability
of the current results to other populations may be limited given
that the NSHS95 cohort was relatively culturally and ethnically
homogeneous (consisting of nearly entirely of white participants).
Second, we only assessed depressive symptoms and did not use
structured diagnostic interviews or physician diagnoses of depres-
sive disorders. However, our analyses did examine the association
of elevated depressive symptoms and probable depressive disorder
with leukocyte telomere length using two cutpoints on the CES-D
that have acceptable sensitivity and specificity in relation to MDD
[23,24] and/or predictive validity with respect to ischemic heart
disease [25]. Third, our data are cross-sectional, and we do not
have repeat assessments of either leukocyte telomere length or of
depressive symptoms. As such, we could not examine life-time
burden of depressive symptoms. In addition, different methods of
measuring leukocyte telomere length may have impacted our
findings. Some researchers have concluded that the PCR method
shows good agreement with the Southern blot method [42], while
others have suggested limitations of the precision of PCR-based
assessments of telomere length [43]. Previous studies of depression
and leukocyte telomere length have used either PCR-based
methods [15,16] as in our study or Southern blot-based methods
[4,13,14]. To our knowledge, no prior study has directly compared
the various methods of measuring leukocyte telomere length with
respect to their associations with depression, and this issue deserves
consideration in future research. Finally, we did not measure
telomerase levels, which one previous study has shown as being
significantly related to depressive symptom severity [44].
Notwithstanding these limitations, the results of this large,
representative, population-based study, which was adequately
powered to detect small but important associations between
depressive symptoms and leukocyte telomere length, suggest that
concurrent depressive symptoms are not associated with shorter
leukocyte telomere length. In addition, elevated depressive
symptoms, probable depressive disorder, and specific depressive
symptom clusters were all unrelated to leukocyte telomere length
in this sample. Future research should further investigate whether
chronicity of depression or early life trauma are associated with
telomere length.
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